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Association between survival 
and levetiracetam use 
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treated with temozolomide 
chemoradiotherapy
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Se Hoon Kim 4, Seok‑Gu Kang 2 & Jong Hee chang 2*
This study was conducted to assess whether levetiracetam (LEV) affects the survival of patients 
with glioblastoma (GBM) treated with concurrent temozolomide (tMZ) chemotherapy. to this end, 
from 2004 to 2016, 322 patients with surgically resected and pathologically confirmed isocitrate 
dehydrogenase (IDH)‑wildtype GBM who received tMZ‑based chemoradiotherapy were analysed. 
the patients were divided into two groups based on whether LeV was used as an anticonvulsant both 
at the time of surgery and the first visit thereafter. The median overall survival (OS) and progression-
free survival (PFS) were compared between the groups. The OS was 21.1 and 17.5 months in the LEV 
(+) and LEV (−) groups, respectively (P = 0.003); the corresponding PFS was 12.3 and 11.2 months 
(P = 0.017). The other prognostic factors included age, extent of resection,  O6‑methylguanine‑DnA 
methyltransferase (MGMT) promoter methylation status, and Karnofsky Performance Status (KPS) 
score. The multivariate analysis showed age (hazard ratio [HR], 1.02; P < 0.001), postoperative 
KPS score (HR 0.99; P = 0.002), complete tumour resection (HR 0.52; P < 0.001), MGMT promoter 
methylation (HR 0.75; P < 0.001), and LEV use (HR 0.72; P = 0.011) were significantly associated with 
oS. in conclusion, LeV use was associated with prolonged survival in patients with GBM treated with 
concurrent tMZ chemoradiotherapy.
Glioblastoma (GBM) is one of the most malignant brain tumours. To improve the survival of patients with 
GBM, surgery should be performed to remove as much of the tumour as possible, followed by chemotherapy 
and  radiotherapy1, 2. Despite the standard therapy, the median overall survival (OS) of patients with GBM is 
only 14.6–20.2 months2–4. Temozolomide (TMZ), the chemotherapy agent for GBM, is an alkylating agent that 
causes the methylation of DNA, resulting in anticancer  effects5, and GBMs with methylated  O6-methylguanine 
DNA methyltransferase (MGMT) promoters are more sensitive to  TMZ5, 6.
Approximately 30–50% of patients with brain tumours present with seizures, and 29–49% of patients with 
GBM experience  seizures7. However, the need for prophylactic antiepileptic drug (AED) therapy in asympto-
matic patients remains controversial. Several neurosurgeons use prophylactic AEDs for various durations after 
brain tumour  surgery8–11. Because AEDs are often combined with chemotherapy, it has been a topic of interest 
to identify AEDs that are most beneficial when used concomitantly with TMZ.
Seizures reduce the quality of life of patients with glioma. Our treatment policy for patients with GBM was to 
use prophylactic AEDs and maintain it for as long as possible unless adverse drug reactions occur. In our institu-
tion, valproic acid (VPA) has been the first-choice AED since 2004. Since 2010, levetiracetam (LEV) gradually 
open
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replaced VPA. LEV belongs to a newer group of AEDs that do not induce or inhibit cytochrome  P45012. Currently, 
it is widely used as it causes fewer adverse events and drug  interactions8, 9, 13–19.
A recent study showed that LEV inhibited MGMT and sensitised GBM cells to  TMZ20. Another study showed 
that patients who received LEV in combination with TMZ had longer OS and progression-free survival (PFS) 
than those who did not receive  LEV21. Therefore, in this study, we investigated whether the use of LEV afforded 
any survival benefit.
Methods
patient recruitment. From 2004 to 2016, 429 consecutive patients with surgically resected and pathologi-
cally confirmed GBM treated with TMZ-based chemoradiotherapy in Yonsei University Severance Hospital in 
Seoul, Korea, were retrospectively reviewed. Patients younger than 18 years of age and those who received only 
radiation or only chemotherapy were excluded from this study. All patients were tested for the IDH1 muta-
tion. As the IDH2 mutations are rare in adults with GBM, we did not test for these. Eighteen of 340 patients 
with GBMs were found to have the IDH1 mutation and were excluded from the analysis. Finally, 322 patients 
were included in the study. This retrospective human study was approved by the institutional review board of 
Yonsei University Severance Hospital (Approval no. 4-2019-1069), which waived the requirement of obtaining 
informed consent. All methods were performed in accordance with the relevant guidelines and regulations.
During the study period, ten neurosurgeons performed glioma surgery at our institution. The institution’s 
policy was to administer AEDs (selected according to the preference of the surgeon) upon initial discovery of 
GBM tumour-induced seizures. After tumour resection, AEDs were administered as prophylaxis regardless of 
seizure history. AEDs were administered as monotherapy unless the patient presented a new seizure event. As 
a starting dose, 1,000 mg/day of VPA or LEV was administered. If a seizure event occurred thereafter, 500 mg/
day of VPA or LEV was added. If additional seizure events occurred, other AEDs were added. In patients with 
neuralgia, 900 mg/day of gabapentin or 150 mg/day of pregabalin was added and escalated by symptoms. That 
therapy was maintained unchanged unless serious adverse events occurred. Information on duration of main-
tenance on the initial prophylactic AED therapy was collected.
The patients were divided into two groups based on whether LEV was used as the anticonvulsant during 
chemoradiotherapy and adjuvant chemotherapy. If LEV was included and administered at both baseline and the 
first visit after the concomitant phase of chemoradiotherapy, the patients were classified into the ‘LEV (+)’ group. 
Patients who were not taking LEV on both occasions were classified into the ‘LEV (−)’ group.
Surgery and adjuvant treatment. Postoperative magnetic resonance imaging (MRI) was performed 
for all patients within 72 h after the surgery. The extent of resection was determined based on the MRI find-
ings. Complete resection was defined as the absence of an enhancing lesion on T1-weighted contrast-enhanced 
images. If there were existing residual tumours in the operation field, the patient was considered to have under-
gone an incomplete resection even if postoperative MRI showed no residual tumour.
Concomitant chemoradiotherapy (CCRT) with TMZ followed by adjuvant TMZ therapy according to Stupp’s 
regimen was started for all  patients3. The patients received radiation therapy at a total dose of 60 Gy, with daily 
fractions of 2 Gy. The follow-up MRI was performed after CCRT, and then after the third and sixth cycles of 
TMZ. Thereafter, MRI was performed every 3–6 months to assess the disease status. The Response Assessment in 
Neuro-Oncology criteria were used to determine disease  progression22. During chemoradiotherapy and adjuvant 
chemotherapy, treatment-related adverse events were graded according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events ver. 4.0.3.
Molecular analysis. The MGMT promoter methylation status was tested using a methylation specific-pol-
ymerase chain reaction (PCR) method as described  previously6. The IDH1 mutation was tested using immuno-
histochemistry with anti-human IDH1 R132H mouse monoclonal antibody (clone H09L, Dianova, 1:80 dilu-
tion), peptide nucleic acid-mediated PCR clamping, or a direct sequencing method.
Statistical analysis. Categorical variables were compared using the chi-square test or Fisher’s exact test. 
Continuous variables were compared using Student’s t test, assuming equal variance, and P values were calcu-
lated using a two-tailed test. Mann–Whitney test was used for non-parametric statistics. Survival was analysed 
using the Kaplan–Meier method and compared using the log-rank test. OS was defined as the time from first 
surgery until death. PFS was defined as the time from the first surgery until disease progression (as confirmed by 
radiologic study) or death. The reverse Kaplan–Meier estimator was used for measuring the duration of follow-
up and duration of AED administration. The Cox-proportional hazards model with a backward stepwise method 
was used for multivariate analysis. The results with a P value of < 0.05 were considered statistically significant.
Results
Patient characteristics are summarised in Table 1. The median age of the patients was 58 (range 19–79) years. 
The patients included 141 women and 181 men. Seizures were the presenting symptom in 33 patients (10%). 
The median preoperative and postoperative Karnofsky Performance Status (KPS) scores were 80 (range 30–100) 
and 70 (range 10–100), respectively. One hundred and seventy-one patients (53%) had undergone complete 
resection. LEV was the most frequently used AED (169 patients, 53%) and used at 500 mg twice a day in most 
cases. The second most frequently used AED was VPA (132 patients, 42%) at a dose of 500 mg twice a day. One 
patient in the LEV (+) group received both LEV and VPA. The MGMT promoter methylation status was avail-
able for 296 (92%) patients. Among them, 87 (29%) showed methylation of the MGMT promoter. The median 
follow-up period was 60.8 (95% confidence interval [CI] 52.2–69.4) months and the median duration of AED 
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administration was 37.3 (95% CI 22.8–51.8) months, as determined using the reverse Kaplan–Meier method. 
For the entire cohort (322 patients), the median OS and PFS were 19.4 (95% CI 16.9–21.9) and 12.0 (95% CI 
10.8–13.1) months, respectively. Two hundred and fifty-five (79%) patients died by the time of analysis. Tumour 
progression was observed in 282 (88%) patients by the time of analysis.
Table 2 shows the characteristics of each group of patients. One hundred and sixty-nine (52%) patients 
received LEV during CCRT. The age and sex of the patients, preoperative history of seizure, and MGMT promoter 
methylation status were not significantly different between the two groups. The LEV (+) group showed higher 
Table 1.  Patient demographics (N = 322). KPS Karnofsky Performance Status, AED antiepileptic drug, CCRT 
concurrent chemoradiotherapy, LEV levetiracetam, MGMT  O6-methylguanine-DNA methyltransferase, CI 
confidence interval.
Parameter No. of patients (%)




Seizure as a presenting symptom 33 (10)






AED during CCRT and adjuvant chemotherapy
LEV included 169 (53)
 LEV only 157 (49)
 LEV plus others 12 (4)
LEV not included 153 (48)
 Valproic acid only 111 (35)
 Valproic acid plus others 21 (7)
 Others 20 (6)





Median follow-up duration, months (95% CI) 60.8 (52.2–69.4)
Median AED maintenance duration, months (95% CI) 37.3 (22.8–51.8)
Overall survival, months (95% CI) 19.4 (16.9–21.9)
Dead 255 (79)
Progression-free survival, months (95% CI) 12.0 (10.8–13.1)
Tumour progression 282 (88)
Table 2.  Patient demographics according to the use of levetiracetam. LEV levetiracetam, SD standard 
deviation, KPS Karnofsky Performance Status, MGMT  O6-methylguanine-DNA methyltransferase.
Parameters
No. of patients (%)
P value
LEV (+) LEV (−)
n = 169 n = 153
Age: mean ± SD 55 ± 12 57 ± 13 0.184
Men 97 (57) 84 (55) 0.652
Seizure as a presenting symptom 22 (13) 11 (7) 0.085
Preoperative KPS: mean ± SD 77 ± 15 72 ± 14 0.001
Postoperative KPS: mean ± SD 72 ± 18 68 ± 17 0.044
Complete resection 106 (63) 65 (42)  < 0.001
Methylated MGMT promoter 47/164 (29) 40/132 (30) 0.758
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preoperative and postoperative KPS scores than the LEV (−) group. Furthermore, the LEV (+) group was more 
likely to undergo complete resection than the control group (63% vs 42%, P < 0.001). The median duration of AED 
maintenance was 31.3 months (95% CI 19.9–42.6 months) in the LEV (+) group. The median duration of AED 
maintenance in the LEV (−) group was not obtained because most patients were administered AEDs until death.
The median OS in the LEV (+) and LEV (−) groups was 21.1 (95% CI 7.1–25.1) and 17.5 (95% CI 14.5–20.5) 
months, respectively (P = 0.003). The corresponding median PFS was 12.3 (95% CI 10.6–13.9) and 11.2 (95% CI 
8.9–13.6) months (P = 0.017) (Fig. 1a).
Additionally, we compared the LEV monotherapy group (157 patients) with the VPA monotherapy group 
(111 patients). The median OS was 21.9 months (95% CI 17.3–26.5) in the former and 18.7 months (95% CI 
14.3–23.1) (P = 0.016) in the latter. The median PFS was 13.3 months (95% CI 11.6–14.9) in the LEV group and 
12.7 months (95% CI 9.4–16.1) in the VPA group (P = 0.082) (Fig. 1b).
In the multivariate analysis, age (P < 0.001; HR 1.02; 95% CI 1.01–1.03), postoperative KPS score (P = 0.002; 
HR 0.99; 95% CI 1.01–1.03), complete resection (P < 0.001; HR 0.52; 95% CI 0.69–0.40), methylated MGMT 
promoter (P < 0.001; HR 0.75; 95% CI 0.65–0.87), and LEV use (P = 0.011; HR 0.72; 95% CI 0.55–0.93) were 
significant prognostic factors for OS (Table 3). Age, postoperative KPS score, complete resection, and methyl-
ated MGMT promoter were also significant factors influencing the PFS, whereas LEV use was not (P = 0.078; 
HR 0.80; 95% CI 0.63–1.03).
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Figure 1.  (a) Kaplan–Meier survival curves showing the overall survival and progression-free survival of 
patients. The overall survival was 21.1 months in the LEV (+) group and 17.5 months in the LEV (−) group 
(P = 0.003). The progression-free survival was 12.3 months in the LEV (+) group versus 11.2 months in the 
LEV (−) group (P = 0.017). (b) Comparison of the LEV monotherapy group and VPA monotherapy group. The 
overall survival was 21.9 months in LEV monotherapy group and 18.7 months in VPA monotherapy group 
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Discussion
Although the use of prophylactic AEDs in patients with brain tumour without a seizure is controversial, a 
survey conducted by the American Association of Neurological Surgeons/Congress of Neurological Surgeons 
showed that approximately 63% of neurosurgeons used AEDs after brain tumour surgery in patients without a 
history of  seizures9. Therefore, some patients are being administered TMZ and an AED together when receiv-
ing chemoradiotherapy. Hence, there has been a lot of interest about AEDs that would be beneficial for patients 
when combined with TMZ.
Phenytoin was the most commonly used AED during the perioperative period until the early  2000s13, 23. 
However, phenytoin induces hepatic cytochrome P450 and has several drug interactions, including interactions 
with chemotherapy  agents24. VPA gradually replaced phenytoin, because it has fewer drug  interactions24. Fur-
thermore, there were reports that VPA extends the survival of patients with  GBM25–30. The exact mechanism of 
this survival benefit is unclear; some in vitro studies revealed, as a histone deacetylase, VPA promotes tumour cell 
differentiation, apoptosis, and growth  arrest31, 32. Another study showed that VPA down-regulates the expression 
of MGMT and sensitises glioma cells to  TMZ33.
Nevertheless, the largest study, which analysed four contemporary randomised clinical trials in newly diag-
nosed patients with GBM, failed to reveal any survival benefit afforded by the AEDs  used34. Another large study 
based on the Cancer Registry of Norway also failed to show survival differences after AED use in 1,263 patients 
with  GBM35.
These studies did not provide information about the duration of AED use. According to the AANS/CNS 
survey, only 16% of neurosurgeons use AEDs for more than 6 weeks9. Previous studies may have involved the 
temporary use of LEV after surgery, which is why LEV may not have affected survival. In our study, the group-
ing was based on the AEDs administered during the first 2 months, as the time-dependent selection bias could 
occur on the basis of long-term criteria. As our policy was to maintain the AEDs if there were no significant 
adverse drug reactions, the AEDs were administered with TMZ during CCRT and the adjuvant chemotherapy 
period in most patients. The median duration of follow-up and AED use were 60.8 months and 37.3 months, 
respectively, in our study. Results from the application of the reverse Kaplan–Meier estimator can be interpreted 
as follows: if a patient had not died, he or she would have been followed for 60.8 months, and AEDs would have 
been administered for 37.3 months.
The survival analysis showed that the OS and PFS of the LEV (+) group were longer than those of the LEV (−) 
group. Our findings support the results of the study of Kim et al., in which the survival benefit afforded by LEV in 
103 patients with GBM was analysed. Their study was the first clinical study to suggest that LEV affords a survival 
benefit in patients with GBM. However, the study lacked information about the IDH mutation, which can be a 
confounding factor. We investigated the IDH1 status in all included patients. To the best of our knowledge, our 
study is the largest to assess the survival benefit of LEV in patients with IDH-wildtype GBMs. Given that IDH-
wildtype GBMs have poor outcomes compared with IDH-mutant GBMs, it is surprising that the Kaplan–Meier 
curve showed a plateau after 48 months; the 10-year survival rate was estimated to be 22% in the LEV (+) group.
It is not clear how LEV improves the survival of patients with GBM. Bobustuc et al. reported that LEV 
increases histone deacetylase 1 (HDAC1) transcription and recruits the HDAC1/mSin3A corepressor, which 
binds to the MGMT promoter region mediated by p53. These three components inhibit MGMT  transcription20, 
resulting in TMZ to be more effective. Other in vitro studies have shown LEV enhances the effect of TMZ on 
GBM stem cell proliferation and  apoptosis36, and the tumour-inhibition effect of LEV in combination with TMZ 
in GBM  cells37.
Recent studies have reported that glioma cells form synapses with neurons and are called as neurogliomal 
 synapses38, 39. They revealed that electrical and glutamatergic excitations promote proliferation and invasion of 
glioma cells, thus making the tumour to progress. From this point of view, it can be hypothesised that the long-
term use of AEDs reduces electrical activity and glutamatergic excitation and thus, inhibits the progression of 
glioma.
Table 3.  Univariate and multivariate analyses of prognostic factors for overall survival and progression-
free survival. HR hazard ratio, CI confidence interval, KPS Karnofsky Performance Status, MGMT  O6-
methylguanine-DNA methyltransferase, LEV levetiracetam.
Overall survival Progression-free survival
Univariate Multivariate Univariate Multivariate
P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI)
Age 0.005 1.02 (1.01–1.03)  < 0.001 1.02 (1.01–1.03) 0.007 1.01 (1.00–1.02)  < 0.001 1.02 (1.01–1.03)
Preop. KPS 0.004 0.99 (0.98–1.00) – – 0.073 0.99 (0.99–1.00) – –
Postop. KPS  < 0.001 0.99 (0.98–0.99) 0.002 0.99 (0.98–1.00)  < 0.001 0.99 (0.98–0.99) 0.001 0.99 (0.98–1.00)
Complete resec-
tion  < 0.001 0.55 (0.71–0.43)  < 0.001 0.52 (0.69–0.40)  < 0.001 0.55 (0.44–0.70)  < 0.001 0.49 (0.63–0.37)
Methylated 
MGMT promoter 0.001 0.78 (0.68–0.91)  < 0.001 0.75 (0.65–0.87)  < 0.001 0.76 (0.67–0.88)  < 0.001 0.72 (0.63–0.83)
LEV use 0.003 0.69 (0.54–0.88) 0.011 0.72 (0.55–0.93) 0.018 0.75 (0.60–0.95) 0.078 0.80 (0.63–1.03)
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The limitation of this study stems from its retrospective nature. As LEV was introduced relatively recently, 
the LEV (+) group included a more recent cohort of patients. Furthermore, over time, surgeons’ skills improved, 
and the rate of complete resection increased. New technical advances such as the use of 5-aminolevulinic acid 
also helped to achieve complete resection. Therefore, the LEV (+) group included more patients with complete 
resection. To overcome this limitation, we conducted a multivariate analysis including well-recognised prognostic 
factors such as age, KPS score, extent of resection, and MGMT promoter methylation status. The multivariate 
analysis also showed that the use of LEV had a significant effect on survival in addition to the other prognostic 
factors.
The seizure frequency after the surgery was not thoroughly investigated in our study. Nevertheless, consider-
ing that many patients received monotherapy alone, the seizure rate among our patients would be considerably 
lower than that reported  previously7, 8. This can be attributed to the long-term administration of AEDs. LEV was 
administered for a long time without serious adverse drug reactions.
In this retrospective analysis, the long-term use of LEV was associated with extended OS and PFS rates 
in patients with GBM. These results suggest that the choice of AED in patients with brain tumours should be 
carefully considered because it may affect survival. However, as this study had many uncontrolled confounding 
factors, further prospective controlled studies are needed to prove the association between survival and LEV 
use in patients with GBM.
Data availability
All relevant data are within the paper.
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